Vigilant Biosciences, Inc.
www.vigilantbiosciences.comVigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection of oral cancer. Vigilant’s BeVigilant™ product line includes a point-of-care RAPID test that is simple, accurate and cost-effective, empowering healthcare practitioners to improve lives through earlier intervention. The BeVigilant RAPID Test, the first and only technology that measures the tumor-initiating and stem cell associated biomarkers – markers clinically validated to be associated with oral cancer – to aid clinicians in the early detection of oral cancer. The point-of-care BeVigilant RAPID Test uses a simple collection method that is easy to administer and non-invasive for the patient. The test has the potential to benefit adults at risk of oral cancer, with particular emphasis on high-risk populations (i.e., current and former tobacco users, those who consume excessive alcohol, and people with human papillomavirus, HPV-16). The BeVigilant RAPID Test is CE Marked and available in select markets outside of the United States. Leadership: Bill Brodie, Chief Executive Officer Robert T. Hamilton, CPA, Chief Financial Officer Dragan Nebrigic, Ph.D., Chief Operating Officer Ben Beckham, Chief Commercial Officer Michael Donovan, M.D. Ph.D., Chief Clinical Officer
Read moreVigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection of oral cancer. Vigilant’s BeVigilant™ product line includes a point-of-care RAPID test that is simple, accurate and cost-effective, empowering healthcare practitioners to improve lives through earlier intervention. The BeVigilant RAPID Test, the first and only technology that measures the tumor-initiating and stem cell associated biomarkers – markers clinically validated to be associated with oral cancer – to aid clinicians in the early detection of oral cancer. The point-of-care BeVigilant RAPID Test uses a simple collection method that is easy to administer and non-invasive for the patient. The test has the potential to benefit adults at risk of oral cancer, with particular emphasis on high-risk populations (i.e., current and former tobacco users, those who consume excessive alcohol, and people with human papillomavirus, HPV-16). The BeVigilant RAPID Test is CE Marked and available in select markets outside of the United States. Leadership: Bill Brodie, Chief Executive Officer Robert T. Hamilton, CPA, Chief Financial Officer Dragan Nebrigic, Ph.D., Chief Operating Officer Ben Beckham, Chief Commercial Officer Michael Donovan, M.D. Ph.D., Chief Clinical Officer
Read moreCountry
State
Florida
City (Headquarters)
Fort Lauderdale
Industry
Employees
11-50
Founded
2011
Estimated Revenue
$1,000,000 to $5,000,000
Social
Employees statistics
View all employeesPotential Decision Makers
Chief Commercial Officer
Email ****** @****.comPhone (***) ****-****Chief Financial Officer
Email ****** @****.comPhone (***) ****-****Board Member
Email ****** @****.comPhone (***) ****-****Chief Executive Officer
Email ****** @****.comPhone (***) ****-****
Technologies
(21)